Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) Non Operating Income (2019 - 2025)

Historic Non Operating Income for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $2.2 million.

  • C4 Therapeutics' Non Operating Income fell 3722.75% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year decrease of 2321.43%. This contributed to the annual value of $14.4 million for FY2024, which is 8456.13% up from last year.
  • Latest data reveals that C4 Therapeutics reported Non Operating Income of $2.2 million as of Q3 2025, which was down 3722.75% from $2.5 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Non Operating Income high stood at $3.9 million for Q1 2024, and its period low was -$464000.0 during Q2 2021.
  • Over the past 5 years, C4 Therapeutics' median Non Operating Income value was $1.6 million (recorded in 2023), while the average stood at $1.5 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first tumbled by 35490.2% in 2021, then skyrocketed by 597857.14% in 2023.
  • C4 Therapeutics' Non Operating Income (Quarter) stood at -$403000.0 in 2021, then soared by 374.94% to $1.1 million in 2022, then surged by 166.25% to $2.9 million in 2023, then rose by 10.75% to $3.3 million in 2024, then plummeted by 31.25% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $2.5 million for Q2 2025, and $2.8 million during Q1 2025.